Linopristin/flopristin
Linopristin/flopristin (development codes NXL103 and XRP 2868) is an experimental drug candidate under development by Novexel. It is an oral streptogramin antibiotic that has potent in vitro activity against certain Gram-positive bacteria including methicillin resistant Staphylococcus aureus (MRSA), as well as the important respiratory pathogens including penicillin-, macrolide- and quinolone-resistant strains. It is a combination of linopristin and flopristin.
| Combination of | |
|---|---|
| Linopristin | Antibiotic |
| Flopristin | Antibiotic |
| Clinical data | |
| Other names | NXL103; XRP 2868 |
| Identifiers | |
| CAS Number | |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.